但讽刺的是，专利战打得火热，商业化却已悄然加速。全球首款CRISPR疗法Casgevy已获批上市，销售额稳步攀升，多家公司在研管线进入晚期临床。专利归属虽悬而未决，但投资人早已用脚投票：CRISPR相关美股公司市值回暖，Cathie Wood（木头姐 ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

When it was announced in 2023 that the world’s first Crispr-based gene-editing therapy had been approved in the UK there was ...

CRISPR therapy STX-1150 could replace daily cholesterol pills with a single dose, reducing LDL by 50% for 18+ months using reversible gene silencing.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A group of scientists successfully made a bespoke gene ...

What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

This Collection supports and amplifies research related to SDG 2 - Zero hunger, SDG-3 (Good health and well-being), SDG-12 (Responsible consumption and production), and SDG-13 (Climate Action). CRISPR ...